Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2023)
34 slides from Optiscan Imaging's shareholder meeting presentation, Nov 23, 2023
Slide 1: Annual General Meeting
Annual General Meeting 23 November 2023
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 24 November 2022. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor m
Slide 3: Notice
Notice Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure doc
Slide 4: Chairman's Address
Chairman’s Address Mr Robert Cooke Non-Executive Chairman 4
Slide 5: Optiscan Board: Experienced Leadership
Optiscan Board: Experienced Leadership Robert Cooke Dr Camile Farah Sean Gardiner Karen Borg Ron Song Board Chair CEO & MD Non-Executive Director Non-Executive Director Non-Executive Director • 40-year career • Proven track record • Managing • Medtech leader • Track record of in health in organisati
Slide 6: Chairman's Address
Chairman’s Address OPTISCAN CHAIRMAN’S AGM ADDRESS Optiscan Imaging Limited (ASX: OIL) (‘the Company’ or ‘Optiscan’) provides the following Chairman’s address which will be made to the Annual General Meeting of shareholders today. During FY23, the Company continued to build on its foundations whilst
Slide 7: Managing Director's Report
Managing Director’s Report Dr Camile Farah CEO & Managing Director 7
Slide 8: Acknowledgement of Country
Acknowledgement of Country I begin today by acknowledging the Traditional Owners of the land on which we meet, the Wurundjeri and the Boon Wurrung people of the Kulin Nation, and pay my respects to their Elders past, present and emerging. 8
Slide 9: Optiscan: Building Momentum
Optiscan: Building Momentum PURPOSE: To positively transform lives through our leading imaging technology. MISSION: To enable informed decisions for optimised global healthcare. VISION: To be a global leader in digital healthcare solutions. Bold & Courageous STRATEGIC PILLARS Customer Focus Empowerm
Slide 10: Improving Cancer Outcomes with Digital Pathology & Precision Surgery
Improving Cancer Outcomes with Digital Pathology & Precision Surgery 1 2 3 4 5 High, growing Cancer treatment Frozen section Access to quality Traditional healthcare is cancer rates are a lacks accuracy and procedure is time- Challenge histopathology is disperse and varies huge burden on results in
Slide 11: Healthcare Ecosystem Value Proposition
Healthcare Ecosystem Value Proposition Patients, Families & Clinicians & Insurers & Advocates Hospital Executives Healthcare Providers Enhanced accuracy, faster Real-time digital microscopic imaging Established CPT reimbursement codes decisions, better outcomes & diagnostic software for GI applicati
Slide 12: Optiscan: Competitive Advantage
Optiscan: Competitive Advantage Digital imaging solutions for Novel imaging solutions for New standard of precision operating rooms of the future contemporary clinical practice healthcare • Real-time feedback in the Operating • Digital microscopic imaging and • Non-invasive imaging for Room diagnosi
Slide 13: Our Hardware: Differentiated Clinical & Research Devices
Our Hardware: Differentiated Clinical & Research Devices InVivage® Oral Imaging Device ViewnVivo® Research Device FEATURES FEATURES • High resolution images, 1000x real magnification • Our original precision engineered platform technology • Software user interface with AI and Telepathology compatibi
Slide 14: Expanding Areas of Clinical Application
Expanding Areas of Clinical Application Expanding Applications … Revolutionising Healthcare Complexity Intraoperative AI Based Biopsy Channel Integration with Image-guided Telepathology & Identification Compatible Devices Robotics Systems Molecular Surgery Remote Diagnostics & Diagnostics • Real-tim
Slide 15: Optiscan: Towards Proprietary Digital Solutions
Optiscan: Towards Proprietary Digital Solutions Unique Hardware Clinical Practice Proprietary Software Handheld, miniaturised Conventional histopathology Developing proprietary AI and confocal laser unchanged for > 100 years Telepathology capability endomicroscopes Evolution from OEM into Slide-free
Slide 16: Key Achievements - Building Foundations in FY23
Key Achievements - Building Foundations in FY23 Key Achievements FY2023 InVivage FDA Application Regulatory Original FDA application submitted as planned Aug 2022 Optiscan Acquires Intellectual Property Acquisition of 228 clinical and histopathological matched patient Clinical Oct 2022 libraries con
Slide 17: Key Achievements - Achieving Significant Milestones into FY24
Key Achievements - Achieving Significant Milestones into FY24 Key Achievements FY2024 Product $16.7m Entitlement Issue Successful completion of a $16.7m capital raise to develop new July 2023 Development clinical devices and product innovations Key International Congress Presentations Clinical Prese
Slide 18: FY23 Financial Highlights
FY23 Financial Highlights Accelerating commercialization and innovation FY23 Revenues from ordinary activities up ~66% on FY22 to $1.68m • Convivo – Carl Zeiss Meditec: Sales more than doubled from previous year to $1.3m • Pre-clinical system, ViewnVivo®, US commercial sale to a large pharmaceutical
Slide 19: FY24 Year to Date: Cash and Orders
FY24 Year to date Value of orders received to date $720k Convivo CASH $990k (60% of last year’s revenue) Capital raised R&D tax refund $270k $16.7m $670k* ViewnVivo® Key takeaways • High value of sales orders secured within 5 months of FY24 (60% of FY23 revenue) *Estimate to be received by Jan24 • F
Slide 20: Optiscan – Future Product Family Vision
Optiscan – Future Product Family Vision Oral Cervical Surgical Pathology GI Vet Optiscan has selected Design and Industry (D+I), Australia’s leading Complete Design and Development company as its product realization partner, to create Optiscan’s Future Product Family Vision, and have begun delivery
Slide 21: Oral Device
Oral Device IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING NORMAL • Highly accurate and easy to use technology for the diagnosis of oral cancer & precancer • Proven ability to detect oral cancer & precancer • Unparalleled ability to diagnose oral cancer and precancer on-the-f
Slide 22: Surgical Device
Surgical Device IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING BREAST ORAL PRECANCER CANCER SURFACE SURFACE PRECLINICAL CLINICAL MARGIN MARGIN SURGICAL BED CANCER Intraoperative live in vivo imaging for immediate surgical decision making. Rigid scope design for open breast su
Slide 23: Pathology Device
Pathology Device IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING • Ex vivo bedside imaging • Specimen-driven frozen section replacement • Can be used on fresh or fixed tissue • Applications in any soft tissue type • Demonstrated applicability in neurosurgery, oral and breast c
Slide 24: GI Device
GI Device IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING • Development of 2nd generation device First and longest lasting product with most • Flexible scope for colonoscopy, developed evidence base and gastroscopy and endoscopy reimbursement options • Based on previous FDA-cl
Slide 25: Vet Device
Vet Device IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING • Large addressable market with unmet Developing first device specifically designed surgical and pathology need for the needs of the veterinary sector • Varied clinical applications in small animal veterinary practice
Slide 26: Telepathology
Telepathology IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING • Cloud hosted webapp utilizing microservice based architecture for device management, security, storage, and data processing • Custom pathologist web portal interface for data access, real-time telepathology suppor
Slide 27: AI/ML
AI/ML IDEATION PROTOTYPING PRECLINICAL CLINICAL REGULATORY LAUNCH MONITORING • Machine learning and image processing pipeline running directly on the device to process images in real-time • Pipeline broken down into multiple ML and traditional computer vision algorithms for: ➢ Image pre-processing,
Slide 28: Certification Timetable
Certification Timetable Q2 Q3 Q4 Q1 FY23 FY24 FY24 FY25 • Progress AI/ML and • Planned submission to • Real world testing of • Anticipated FDA telepathology portal FDA for De Novo AI/ML and telepathology clearance classification applications • Analysis of oral images to • Launch commercial determine
Slide 29: Expanding our Operation for Commercial Growth
Expanding our Operation for Commercial Growth Melbourne: Global Headquarters R&D and Marketing & Innovation Communications Minnesota, United States Commercial Hub Beijing, China Sinsi Technologies Ltd Engineering HR & Finance Manufacturing Regulatory & and Operations Quality APAC: Distributor Networ
Slide 30: Sales Strategy – Aligned for Revenue Growth
Sales Strategy – Aligned for Revenue Growth Distributor Consolidation US Commercial Operation Outbound Sales & Marketing Market Development • APAC distributor review • Direct market model in North • Outbound digital marketing • Market development to America. Commercial hub lead generation explore ne
Slide 31: Marketing & Communications – Increasing Brand Recognition
Marketing & Communications – Increasing Brand Recognition Increasing Brand Awareness Revenue Generation Increasing Communication Reach Expanding Media Presence • Conferences, publications, • Lead generation activities • 21k reached with email marketing, • Coverage in the AFR, Bulls N’ brand initiati
Slide 32: Business Model: Progressing to Sustainable Revenue Generation
Business Model: Progressing to Sustainable Revenue Generation Entry & Enablement Recurring Revenue Generation Sustainable Revenue Generation Clinical Devices SaMD Solutions Pathology as a Service • Patented portfolio with high intrinsic value • Proprietary AI and Telepathology • Full-scale pathology
Slide 33: Summary
Summary Company Users • Slide-free, biopsy-free live microscopic digital imaging solutions • Image guided surgery & digital pathology at the single cell level for oral, breast, GI and vet • Early detection for physicians • InVivage (oral) and proprietary AI & Telepathology software • Revolutionary v
Slide 34: Thank You Questions?
Thank You Questions?
Optiscan Imaging — Shareholder Meeting (November 2023) on 6ix